Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 65-69

  Byeon, Hyeong Jun ^a   Choi, Seong Ho ^a   Choi, Ji Su ^a   Kim, Tae Hyung ^a   Lee, Eun Seong ^b   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Antitumor efficacy; Apoptotic activity; Mia Paca 2; Pancreatic cancer; PEGylated TRAIL

Indexed keywords

ANTITUMOR EFFICACY; APOPTOTIC ACTIVITY; MIA PACA-2; PANCREATIC CANCER; PEGYLATED TRAIL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895070662     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.10.010     Document Type: Article

References (32)

1. Yu X., Zhang Y., Chen C., Yao Q., Li M. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 2010, 1805:97-104.
2. Tse R.V., Dawson L.A., Wei A., Moore M. Neoadjuvant treatment for pancreatic cancer - a review. Crit Rev Oncol Hematol 2008, 65:263-274.
3. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
4. O'Reilly E.M. Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res 2009, 3:S11-S15.
5. Maalouf G.E., Tourneau C.L., Batty G.N., Faivre S., Raymond E. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 2009, 35:167-174.
6. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
7. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4753-4765.
8. Mellier G., Huang S., Shenoy K., Pervaiz S. TRAILing death in cancer. Mol Aspects Med 2010, 31:93-112.
9. Griffith T.S., Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998, 10:559-563.
10. French L.E., Tschopp J. The TRAIL to selective tumor death. Nat Med 1999, 5:146-147.
11. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001, 7:954-960.
12. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6:564-567.
13. Saito R., Bringas J.R., Panner A., Tamas M., Pieper R.O., Berger M.S., et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004, 64:6858-6862.
14. Roth W., Isenmann S., Naumann U., Kugler S., Bahr M., Dichgans J., et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999, 265:479-483.
15. Matsuzaki H., Schmied B.M., Ulrich A., Standop J., Schneide M.B., Batra S.K., et al. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 2001, 7:407-414.
16. Trauzold A., Roder C., Sipos B., Karsten K., Arlt A., Jiang P., et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. Faseb J 2005, 19:620-622.
17. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486.
18. Khanbolookis S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006, 5:2251-2260.
19. Thomas R.P., Farrow B.J., Kim S., May M.H., Hellmich M.R., Evers B.M. Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 2002, 132:127-134.
20. Ozawa F., Friess H., Kleeff J., Xu Z.W., Zimmermann A., Sheikh M.S., et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001, 163:71-81.
21. Kato S., Shirato K., Imaizumi K., Toyota H., Mizuguchi J., Odawara M., et al. Anticancer effects of phenoxazine derivatives combined with tumor necrosis factor-related apoptosis-inducing ligand on pancreatic cancer cell lines, KLM-1 and MIA-PaCa-2. Oncol Rep 2006, 15:843-848.
22. Jiang H.H., Kim T.H., Lee S., Chen X., Youn Y.S., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 2011, 32:8529-8537.
23. Kim T.H., Jiang H.H., Park C.W., Youn Y.S., Lee S., Chen X., et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J Control Release 2011, 150:63-69.
24. Kim T.H., Jo Y.G., Jiang H.H., Lim S.M., Youn Y.S., Lee S., et al. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Control Release 2012, 162:422-428.
25. Chae S.Y., Kim T.H., Park K., Jin C.H., Son S., Lee S., et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010, 9:1719-1729.
26. Kim T.H., Youn Y.S., Jiang H.H., Lee S., Chen X., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjug Chem 2011, 22:1631-1637.
27. Youn Y.S., Shin M.J., Chae S.Y., Jin C.H., Kim T.H., Lee K.C. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol Lett 2007, 29:713-721.
28. Lim S.M., Kim T.H., Jiang H.H., Park C.W., Lee S., Chen X., et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011, 32:3538-3546.
29. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001, 23:251-258.
30. Westphal S., Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003, 2:1-14.
31. Youn Y.S., Chae S.Y., Lee S., Jeon J.E., Shin H.G., Lee K.C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 2007, 73:84-93.
32. Yan B.M., Van Dam J. Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer. Can J Gastroenterol 2008, 22:405-410.